AKERO THERAPEUTICS INC (AKRO)

Company Profile

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 44 full-time employees. The company went IPO on 2019-06-20. The firm is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.

Company Info

AKERO THERAPEUTICS INC

601 Gateway Boulevard, Suite 350

South San Francisco CALIFORNIA 94080

P: 16504876488.0

CEO: Andrew Cheng

Employees: 44

Website: https://akerotx.com/